Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 07, 2026. The Board recommended a final dividend of ₹7.00 per equity share for FY2025-26, subject to shareholder approval at the ensuing AGM. This, along with the interim dividend of ₹7.00 per equity share (post-bonus adjusted to ₹2.33), brings the total dividend for FY2025-26 to ₹9.33 per equity share. The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a five-year term from the conclusion of the 26th AGM (2026) until the 31st AGM (2031), subject to shareholder approval. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for FY2026-27. Key management and director changes were approved: Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for five years from May 4, 2027, to May 3, 2032. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. The Board also noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah as Non-Executive, Non-Independent Directors, both effective May 07, 2026. Furthermore, the Board approved an investment of up to ₹5.50 crore in the equity shares of Think Health Diagnostics Private Limited, a wholly-owned subsidiary, to support its operations and capital expenditure. The Memorandum of Association (MOA) of the company was also approved for alteration to align with the Companies Act, 2013, and broaden its scope within the healthcare and diagnostics ecosystem. The Board Meeting commenced at 3:35 PM and concluded at 5:40 PM on May 07, 2026.
